309 related articles for article (PubMed ID: 15280463)
21. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
Jung YJ; Choi H; Kim H; Lee SK
J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
[TBL] [Abstract][Full Text] [Related]
22. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
[TBL] [Abstract][Full Text] [Related]
23. Tyrosines 60, 64, and 101 of Epstein-Barr virus LMP2A are not essential for blocking B cell signal transduction.
Swart R; Fruehling S; Longnecker R
Virology; 1999 Oct; 263(2):485-95. PubMed ID: 10544120
[TBL] [Abstract][Full Text] [Related]
24. Identifying the Cellular Interactome of Epstein-Barr Virus Lytic Regulator Zta Reveals Cellular Targets Contributing to Viral Replication.
Zhou Y; Heesom K; Osborn K; AlMohammed R; Sweet SM; Sinclair AJ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694936
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency.
McDonald C; Karstegl CE; Kellam P; Farrell PJ
J Gen Virol; 2010 Mar; 91(Pt 3):622-9. PubMed ID: 19923262
[TBL] [Abstract][Full Text] [Related]
26. Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta.
Zhao M; Nanbo A; Becnel D; Qin Z; Morris GF; Li L; Lin Z
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847852
[TBL] [Abstract][Full Text] [Related]
27. Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency.
Bryant H; Farrell PJ
J Virol; 2002 Oct; 76(20):10290-8. PubMed ID: 12239305
[TBL] [Abstract][Full Text] [Related]
28. Activation of Epstein-Barr virus by saliva from Sjogren's syndrome patients.
Nagata Y; Inoue H; Yamada K; Higashiyama H; Mishima K; Kizu Y; Takeda I; Mizuno F; Hayashi Y; Saito I
Immunology; 2004 Feb; 111(2):223-9. PubMed ID: 15027908
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.
Incrocci R; Hussain S; Stone A; Bieging K; Alt LA; Fay MJ; Swanson-Mungerson M
Cell Immunol; 2015 Oct; 297(2):108-19. PubMed ID: 26255694
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases.
Adamson AL; Darr D; Holley-Guthrie E; Johnson RA; Mauser A; Swenson J; Kenney S
J Virol; 2000 Feb; 74(3):1224-33. PubMed ID: 10627532
[TBL] [Abstract][Full Text] [Related]
31. B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition.
Chen Y; Fachko DN; Ivanov NS; Skalsky RL
mSphere; 2021 Apr; 6(2):. PubMed ID: 33853871
[TBL] [Abstract][Full Text] [Related]
32. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
33. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
[TBL] [Abstract][Full Text] [Related]
34. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.
Ragoczy T; Heston L; Miller G
J Virol; 1998 Oct; 72(10):7978-84. PubMed ID: 9733836
[TBL] [Abstract][Full Text] [Related]
35. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
[TBL] [Abstract][Full Text] [Related]
36. Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.
Kosowicz JG; Lee J; Peiffer B; Guo Z; Chen J; Liao G; Hayward SD; Liu JO; Ambinder RF
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566383
[TBL] [Abstract][Full Text] [Related]
37. Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins.
Li L; Su X; Choi GC; Cao Y; Ambinder RF; Tao Q
BMC Cancer; 2012 Mar; 12():125. PubMed ID: 22458933
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.
Fruehling S; Swart R; Dolwick KM; Kremmer E; Longnecker R
J Virol; 1998 Oct; 72(10):7796-806. PubMed ID: 9733815
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction.
Miller CL; Lee JH; Kieff E; Burkhardt AL; Bolen JB; Longnecker R
Infect Agents Dis; 1994; 3(2-3):128-36. PubMed ID: 7812651
[TBL] [Abstract][Full Text] [Related]
40. Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.
Ye J; Gradoville L; Miller G
J Virol; 2010 Dec; 84(23):12405-18. PubMed ID: 20861250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
